All In Biotech

Drug Trial Radar · NCT07010393

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

335

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Fujian Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render locally advanced, initially unresectable-or high-morbidity-thyroid cancers operable. The primary endpoint is conversion-to-surgery; key secondaries are R0/1 margin rate and 12-month event-free survival, with propensity-score weighting correcting cohort imbalances. Findings aim to define a precision-guided neoadjuvant standard for down-staging advanced thyroid tumors.

Conditions

  • Thyroid Neoplasms

Interventions

  • DabrafenibDrug

    150 mg orally twice daily; ≤4 × 28-day cycles

  • TrametinibDrug

    2 mg orally once daily; same duration

  • SelpercatinibDrug

    160 mg orally twice daily; ≤4 cycles

  • PralsetinibDrug

    retrospective, 400 mg orally once daily; ≤4 cycles

  • LenvatinibDrug

    24 mg orally once daily; ≤4 cycles

  • LarotrectinibDrug

    Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.

  • AnlotinibDrug

    12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)

  • PembrolizumabDrug

    200 mg IV infusion every 3 weeks; ≤4 cycles

  • SintilimabDrug

    200 mg IV infusion every 3 weeks; ≤4 cycles

  • CabozantinibDrug

    Cabozantinib 60 mg orally once daily, continuous 28-day cycles.

  • BemosuzumabDrug

    China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).

  • Conversion SurgeryProcedure

    Conversion Surgery if resectable

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Real-World Progression-Free Survival (rwPFS)Time frame: Baseline to radiologic/clinical progression or death, whichever occurs first, up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.